PubMed Health⌕ Search

Biomedical subjects

K Possinger

Publications and source records attributed to K Possinger.

At least 127 records · Page 7Linked to original sources
PubMed1990

[Breast cancer: adjuvant hormone and chemotherapy].

Indications and types of adjuvant treatment depend on the number of infiltrated axillary lymph nodes, menopausal and hormonal receptor status. In N0 situation is to date no indication for hormonal or cytotoxic therapy outside of clinical trials: disease-free survival may be improved but overall survival is not influenced. In N+ situation premenopausal patients should receive polychemotherapy independent from hormonal receptor status, postmenopausal patients with positive receptor status should be treated with tamoxifen up to 5 years: in this situation disease-free interval and overall survival can be enhanced significantly.

Antineoplastic Agents↗
PubMed1987

Treatment toxicity reduction: breast cancer.

Since curative treatment of advanced breast cancer is still beyond our reach, the importance of reducing overall toxicity of systemic treatment must be stressed. This seems to be possible by adapting the form and intensity of therapy to the prognosis and stage of disease and by using drugs exhibiting high antitumoral efficacy combined with low systemic toxicity. In 475 patients with metastatic breast cancer, we initiated a prognosis-oriented therapeutic strategy. We developed a prognostic score so as to classify patients into 'high' and 'low' risk groups. In this way we were able to separate patients into two groups with statistically different survival times. In addition, we found that the impact of the first polychemotherapy on survival is different when comparing patient with favourable and unfavourable prognostic scores. Patients with favourable prognostic factors had exactly the same survival time independent of tumour progression, stable disease or even partial remission. Only patients achieving a complete remission survived longer. In contrast, patients with unfavourable prognostic factors apparently benefited from chemotherapy. Patients achieving stable disease or objective tumour remission had a significantly longer survival time than those patients with immediate tumour progression. Additionally, for most of the patients in this group, chemotherapy induced a transient stabilization or improvement of tumour induced symptoms. Therefore, we conclude that chemotherapy of advanced breast cancer is necessary. However, to reduce overall toxicity, it must be planned and administered according to the prognostic picture of the individual patient.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1983

[Predictive tumor tests in chemotherapeutic treatment concepts of malignant diseases].

In order to determine the pre-therapeutical effectiveness of cytotoxic drugs in metastasizing tumours, two in vitro test methods were examined for their predictive validity: the short-term incubation of tumour cells with cytotoxic drugs and radioactive labelled precursors of the DNA- or RNA-synthesis, and the testing of the cloning ability of tumour cells, pre-incubated with cytotoxic drugs. The short-term incubation techniques were directed in two directions: the testing of sensitivity and the testing of resistance. Both methods can only be carried out using strong proliferating tumours. With methodical, pharmalogical and biological problems, the sensitivity test results in a relatively minor correlation between the in vitro and in vivo reactions. Contrary to this the resistance test allows a predictive, clinically utilizable judgement of primary and secondary forms of the tumour-cell resistance of specific cytotoxic drugs. The consecutive measurement of the proliferative activity of tumours before and after a systematic chemotherapy also seems to be an able parameter concerning the clinically expected effectiveness of cytotoxic drugs. Compared to the other in vitro tests the tumour-cell clonogenic assay demonstrates two main advantages: firstly, all cytotoxic drugs can be analysed by this test method, and secondly, little proliferating tumours can also examined. Nevertheless, this test method seems to be more suitable for predicting tumour-cell resistance than the sensitivity of cytotoxic drugs.

Antineoplastic Agents↗
PubMed1981

[Clinical aspects and chemotherapy of adenocarcinoma of the kidney].

The classic triad of hematuria, pain and presence of a palpable flank mass is found only in few patients with renal carcinoma. Hematuria, the main symptom, occurs in nearly the half of patients. Blood levels of erythropoetin and renin are often elevated and may be of value as biochemical tumor markers. Chemotherapeutic agents do not alter the course of metastatic renal carcinoma significantly. Vinblastine is the most effective available drug currently. Progestins or androgens cause tumor regression very seldom. If antioestrogens or immuntherapeutic regimens may improve therapeutic results, is not to be decided at present.

Adenocarcinoma↗
PubMed1981

[Inhibition of 3H-TdR-incorporation in tumor cells after application of cytotoxic drugs as an indicator of therapeutical efficacy (author's transl)].

In 36 Walker-ascites-carcinosarcoma bearing rats the reduction of 3H-TdR-incorporation into tumor cells after cytotoxic treatment as an potential prognostic factor for efficacy of chemotherapy was tested. Twelve rats each were i.p. treated with 1 mg/kg bw. DDP resp. 0.8 mg/kg bw. adriamycin. Twelve rats were injected with 0.2 mg phs. NaCl and served as control. Survival of rats served as criterion of therapeutic efficacy. There was a significant correlation between reduction of 3H-TdR-uptake in tumor cells after cytotoxic therapy and survival.

Animals↗
PubMed1981

[Current status of chemotherapy of gastric and colorectal cancer].

The group of gastric and colorectal carcinomas has the highest cancer mortality in Western Germany. The possibilities of treatment with chemotherapy only have palliative character. 5-Fluourouracil is the therapeutic of choice on the metastasized colorectal cancer. However, a prolongation of survival time by treatment of the colorectal tumor could neither be recorded in applying 5-Fluorouracil as a single agent, nor through combination chemotherapy. The treatment of the metastasized gastric carcinoma with combinations consisting of the 5-Fluorouracil and Adriamycin could be of future value. Also effective with this tumour as a palliative measure is the combined treatment with 5-Fluorouracil and irradiation. The advantage of an adjuvant therapy of a chemotherapeutical, radiological or immunological kind could so far not be proved.

Colonic Neoplasms↗
PubMed1980

[In vitro resistance testing of tumors in relation to cytostatics. 1. Animal experiments].

By studying rat Yoshida sarcoma and Walker carcinoma, pertinent results have been obtained for chemotherapy drug (CD) resistance of human tumors. The incorporation rates of tritiated metabolic precusors of DNA and RNA synthesis could be shown to be reproducible in ascites tumor cells and in solid tumor cells, in the absence as well as in the presence of CDS. Fraction of proliferation cells, cell cycle phase duration and tumor generation time were equal before and after explanation. The in vitro CD concentration used did not promote cell death within the first 4 h post-explantation, as shown by supravital stain (with Lissamin green and Trypan blue) and by 51Cr-release studies.

Animals↗